Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, aged ≥ 55 to ≤ 90.~* Received oral bisphosphonate therapy for at least 3 years immediately prior to screening~* BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck~* History of nonvertebral fracture after age 50, or vertebral fracture.~Exclusion Criteria:~* Use of other agents affecting bone metabolism including Strontium ranelate, fluoride (for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH) analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators (SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic glucocorticosteroids:~* History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.~* Vitamin D insufficiency, defined as 25 (OH) vitamin D levels \< 20 ng/mL, as determined by the central laboratory.~* Current hyper- or hypocalcemia~* Current, uncontrolled hyper- or hypothyroidism

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Teriparatide (Type: ACTIVE_COMPARATOR): Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).